探究西格列汀与二甲双胍同用对2型糖尿病患者血糖指标水平及疗效的影响

丁辛耘

[摘要] 目的 探究西格列汀与二甲双胍同用对2型糖尿病患者血糖指标水平及疗效的影响。方法 将2018年11月—2019年11月该院收治的148例2型糖尿病患者随机分为对照组与试验组，每组74例，对照组以二甲双胍治疗，试验组在对照组基础上加用西格列汀治疗;比较两组治疗前后空腹血糖、餐后2 h血糖、糖化血红蛋白水平，比较两组临床疗效与不良反应发生率。结果 治疗后，两组空腹血糖等上述指标水平均较治疗前显著下降（P<0.05），且试验组显著低于对照组（P<0.05）;试验组有效率91.89%显著高于对照组79.73%，（P<0.05）;两组不良反应发生率差异无统计学意义（P>0.05）。结论 西格列汀与二甲双胍同用治疗2型糖尿病可显著降低患者空腹血糖等多项血糖指标水平、提高临床疗效且安全可靠。

[关键词] 2型糖尿病;西格列汀;二甲双胍;空腹血糖;餐后2 h血糖;糖化红蛋白

[中图分类号] R587.1          [文献标识码] A          [文章编号] 1672-4062（2020）09（b）-0066-03

Explore the Effects of Sitagliptin and Metformin on Blood Glucose Levels and Curative Effects in Patients with Type 2 Diabetes

DING Xin-yun

Department of Internal Medicine， Shanghai Hudong Hospital， Shanghai， 200129 China

[Abstract] Objective To explore the effect of sitagliptin and metformin on blood glucose levels and curative effects in patients with type 2 diabetes. Methods 148 patients with type 2 diabetes admitted to the hospital from November 2018 to November 2019 were randomly divided into a control group and a test group， 74 cases in each group. The control group was treated with metformin， and the test group was added sitagliptin treatment; compare the fasting blood glucose before and after treatment， 2 h postprandial blood glucose， and glycosylated hemoglobin levels between the two groups， and compare the clinical efficacy and the incidence of adverse reactions between the two groups. Results After treatment， the levels of the above indicators such as fasting blood glucose in the two groups were significantly lower than before treatment（P<0.05）， and the experimental group was significantly lower than the control group （P<0.05）; the effective rate of the experimental group 91.89% was significant， higher than the control group 79.73%（P<0.05）; there was no statistically significant difference in the incidence of adverse reactions between the two groups（P>0.05）. Conclusion The simultaneous use of sitagliptin and metformin in the treatment of type 2 diabetes can significantly reduce the fasting blood glucose and other blood glucose indicators， improve the clinical efficacy， and is safe and reliable.

[Key words] Type 2 diabetes; Sitagliptin; Metformin; Fasting blood glucose; 2 h postprandial blood glucose; Glycosylated globin

糖尿病是臨床常见的慢性代谢性疾病，在糖尿病患者中2型糖尿病所占比重高达90%，高血糖为该病主要临床特征，一般情况下，高血糖多由胰岛素分泌缺陷与胰岛素抵抗所致。患者常常由于血糖增高引起血管、眼、神经等机体多处组织、器官功能障碍，严重时引起电解质紊乱、酸碱失衡甚至酸中毒和高渗昏迷等，严重危害患者生命健康，影响其生活质量[1-2]。调节血糖仍是治疗糖尿病的首要目标，临床上通常以饮食调节、增强运动、服用降糖药等多种途径治疗[3]。虽然治疗途径多样，但大部分患者仍难将血糖下调至理想状态，因此，寻找更安全有效的治疗方法乃治疗该病的关键任务。二甲双胍为临床常用降糖药，该药在糖尿病治疗中，短期疗效显著，长期的血糖控制效果尚不理想;西格列汀是近年新研发的新型降糖药，该药可通过增强长促胰岛激素活性，使胰岛素分泌量增加，进而实现对胰岛素的调节与控制。该次研究将以二者联合治疗2018年11月—2019年11月至该院就诊的148例2型糖尿病患者，以观二者联用对患者血糖指标水平及临床疗效的影响，现报道如下。